Monash IVF Could Become a Takeover Target for Private Equity — Market Talk
Jun 13, 2025, 10:59 GMT+10Less than 1 min read
The steep fall in Monash IVF's share price following another incident at one of its laboratories has raised the chances of it becoming a takeover target, reckons Ord Minnett. Monash IVF's share price fell by around 1/4 after it disclosed a new incident at its Clayton laboratory in southeastern Australia. That extended a stock decline that happened after an earlier incident in Brisbane. Monash IVF's CEO has since resigned. Analyst Tom Godfrey says these developments have heightened risks including weaker new patient volumes, potential doctor losses and increased regulation. "With Monash IVF now trading at 6.7x adjusted Ebitda (versus competitors at >12x) we see increased risk of Private equity/strategic interest," Ord Minnett says. Monash IVF is up 1.5% at A$0.67.
MVF Price at posting:
65.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)